TXG · 10x Genomics, Inc.

Current Thesis

10x Genomics' recovery thesis now turns on Atera deliveries and revenue execution: shipment of approximately 40 instruments in the second half of 2026 and full-year revenue within management's $610–630 million guidance would substantiate the operating case before a weekly close below $58.57 invalidates the price structure. Those operating benchmarks come from the August 6, 2026 earnings release and call. The September 18, 2026 Friday close of $76.60 clears the earlier published weekly confirmation threshold of $65.12; that price test has been met, while shipment conversion remains unresolved.

As an inference, the narrative is maturing — RBC's September 1, 2026 initiation and UBS's September 9 target revision date the progression from the launch announcement into analyst coverage. RBC assigned Sector Perform with a $70 target; UBS retained Neutral with a $68 target. These observations establish attention, but the sample is too small to establish expanding participation or exhausted demand. Confirmed Atera deliveries accompanied by a broader sequence of operating-estimate upgrades would challenge the maturing interpretation. Analyst-action history.

Bullish and bearish views on 10x Genomics, Inc.

The model's bull view on 10x Genomics, Inc. (TXG), in brief: Launch demand exceeds shipment plans. On the August 6, 2026 earnings call, management said Atera orders greatly exceeded approximately 40 instruments planned for second-half 2026 shipment. This supports the demand component of the recovery inference; deferral into 2027 would… The bear view: Underlying revenue growth remains modest. Both cases follow in full.

Bull Case

• Launch demand exceeds shipment plans. On the August 6, 2026 earnings call, management said Atera orders greatly exceeded approximately 40 instruments planned for second-half 2026 shipment. This supports the demand component of the recovery inference; deferral into 2027 would break its delivery timetable.
• Management raised annual revenue guidance. The August 6, 2026 results increased full-year revenue guidance to $610–630 million from $600–625 million. A subsequent reduction below the revised range would contradict that improvement. Filed results release.
• Patent enforcement secured a verdict. On August 28, 2026, the company announced a willful-infringement verdict against Parse and damages exceeding $4.8 million. The contemplated competitive restriction remains conditional on a permanent US injunction; denial would invalidate that prospective benefit. Company announcement.

Bear Case

• Underlying revenue growth remains modest. The August 6, 2026 release reported second-quarter revenue of $151.0 million versus $172.9 million a year earlier, with growth of 3% after excluding patent-settlement revenue. That reported operating growth provides limited confirmation for the market's 132.5% three-month advance through September 18, 2026. Filed results release.
• Shipment completion is still unmeasured. The August 6, 2026 call supplied a planned shipment count, while the evidence available for this September 20, 2026 assessment contains no completed Atera shipment count. Orders alone cannot establish delivery or recognized revenue.
• Quarterly margin includes a benefit. The August 6, 2026 release reported second-quarter gross margin of 74%, including $2.6 million of tariff refunds. That observation does not establish a recurring margin at the reported level. Filed results release.

Setup & Price Structure

The adjusted market series records a September 18, 2026 close of $76.60, 0.5% below its $76.97 52-week high, following a three-month increase of 132.5%. The 14-period relative strength index (RSI) was 77.8 on that date. These are measured momentum observations; they do not identify who supplied demand or establish that a reversal is imminent.

September 18 was the week's final trading session, so its close resolves the weekly confirmation question left open in the September 11 publication. The previously published $58.57 August shelf remains the thesis-break threshold. Clearing $65.12 establishes the earlier price outcome; it does not establish Atera execution.

The September 18 close also exceeds RBC's September 1 target of $70 and UBS's September 9 target of $68. That comparison shows price advancing beyond those published analyst assessments. No moving-average reading, comparable short-interest series or quantified retail-participation measure is available here, so distance above trend and crowding cannot be measured. Analyst-action history.

Catalyst Calendar (next 30 days)

• 2026-09-24 — Short-interest publication. FINRA schedules publication of the September 15, 2026 settlement snapshot. A comparable preceding observation would permit assessment of reported short-interest changes; the release cannot establish the source of long demand or Atera deliveries. FINRA calendar.
• 2026-10-09 — Subsequent short-interest publication. FINRA schedules publication of the September 30, 2026 settlement snapshot. This supplies another positioning observation, without resolving the operating thesis. FINRA calendar.

As checked on September 20, 2026, the company's investor-events page lists no upcoming events. No company-confirmed earnings or Atera shipment date is available for the next 30 days; management's August 6 shipment plan specifies the second half of 2026 rather than an exact delivery date. Company event calendar.

What Would Change Our Mind

Loss of the previously identified August shelf would break the continuation structure: a weekly close below $58.57 is the observable price invalidation retained from the September 11, 2026 publication. The operating case would separately weaken if management deferred its August 6 plan for approximately 40 second-half shipments into 2027 or reduced full-year revenue guidance below $610–630 million.

The positive resolution requires reported Atera shipments consistent with that plan and full-year revenue within the disclosed range. The September 18, 2026 close confirms price strength only. The evidence supports medium conviction because the earlier price hurdle has cleared while delivery evidence remains missing.

Correlation Notes

This remains a single-company recovery assessment. The September 18, 2026 evidence supplies TXG's price change but no matched peer or index return series; it cannot support a measured correlation claim or establish a genomics-wide advance. The August 6 Atera shipment plan and August 28 Parse verdict provide company-specific mechanisms, but their individual contributions to the rally cannot be isolated from the supplied observations.